Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Acrivastine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 3/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 3/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 3/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 2/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.58 |
| ▸ | THPO | P40225 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.57 |
| ▸ | GMNN | O75496 | 1/20 | 0.57 |
| ▸ | BLM | P54132 | 1/20 | 0.57 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acrivastine SCHEMBL4703 | 1.00 | ADRA1A (1.00) | ADRA1AHRH1OPRK1SLC6A4PTGS2 | |
| Acrivastine SCHEMBL5053832 | 1.00 | ADRA1A (1.00) | ADRA1AHRH1OPRK1SLC6A4PTGS2 | |
| Acrivastine SCHEMBL15392862 | 1.00 | ADRA1A (1.00) | ADRA1AHRH1OPRK1SLC6A4PTGS2 | |
| Acrivastine SCHEMBL29414102 | 1.00 | ADRA1A (1.00) | ADRA1AHRH1OPRK1SLC6A4PTGS2 | |
| Acrivastine SCHEMBL4702 | 1.00 | ADRA1A (1.00) | ADRA1AHRH1OPRK1SLC6A4PTGS2 | |
| Acrivastine SCHEMBL11034921 | 1.00 | ADRA1A (1.00) | ADRA1AHRH1OPRK1SLC6A4PTGS2 | |
| Acrivastine SCHEMBL2832062 | 0.99 | ADRA1A (0.98) | ADRA1AHRH1OPRK1SLC6A4PTGS2 | |
| Acrivastine SCHEMBL9561912 | 0.98 | ADRA1A (0.96) | ADRA1AHRH1OPRK1SLC6A4PTGS2 | |
| Acrivastine SCHEMBL9561915 | 0.98 | ADRA1A (0.96) | ADRA1AHRH1OPRK1SLC6A4PTGS2 | |
| SCHEMBL10505907 | 0.92 | SLC6A4 (0.84) | ADRA1AHRH1OPRK1SLC6A4PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2849738-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | Techfields Pharma Co., Ltd. (CN) | 2015-03-25 | — | — | EP | disclosed |
| WO-2013170655-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | TECHFIELDS PHARMA CO., LTD. (CN) | 2013-11-21 | — | — | WO | disclosed |
| WO-1996033997-A1 | BENZIMIDAZOLE DERIVATIVES BEING DUAL HISTAMINE (H1) AND PLATELET ACTIVATING FACTOR (PAF) ANTAGONISTS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1996-10-31 | — | — | WO | disclosed |